ZyVersa Therapeutics Inc. (ZVSA) - Total Liabilities
Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) has total liabilities worth $12.77 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is ZyVersa Therapeutics Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
ZyVersa Therapeutics Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is ZyVersa Therapeutics Inc.'s balance sheet.
ZyVersa Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of ZyVersa Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Condmag Brasov
RO:COMI
|
Romania | RON11.76 Million |
|
Future Enterprises Limited
NSE:FELDVR
|
India | Rs61.23 Billion |
|
GIGLIO GROUP S.P.A. O.N.
F:5JR
|
Germany | €25.22 Million |
|
Regent Pacific Properties Inc
V:RPP
|
Canada | CA$19.99 Million |
|
Olenox Industries Inc.
NASDAQ:OLOX
|
USA | $29.17 Million |
|
Noratis AG
XETRA:NUVA
|
Germany | €347.30 Million |
|
Yimutian Inc. American Depositary Shares
NASDAQ:YMT
|
USA | $1.55 Billion |
|
Tessin Nordic Holding AB
ST:TESSIN
|
Sweden | Skr221.96 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down ZyVersa Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ZVSA equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZyVersa Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual total liabilities of ZyVersa Therapeutics Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $12.08 Million | +9.45% |
| 2023-12-31 | $11.04 Million | -40.36% |
| 2022-12-31 | $18.51 Million | +35.85% |
| 2021-12-31 | $13.63 Million | +47.42% |
| 2020-12-31 | $9.24 Million | -- |
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more